Canine transmissible venereal tumor and seminoma: a cytohistopathology and chemotherapy study of tumors in the growth phase and during regression after chemotherapy

In this study, 12 dogs affected by canine transmissible venereal tumor (CTVT) and testicular seminoma tumor were studied retrospectively. The cytological sample was smeared onto a glass slide and either air-dried for May-Grünwald-stain, and masses were surgically removed. The tumors were grossly exa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Tumor biology 2014-06, Vol.35 (6), p.5493-5500
Hauptverfasser: Javanbakht, J, Pedram, B, Taheriyan, M R, Khadivar, F, Hosseini, S H, Abdi, F S, Hosseini, E, Moloudizargari, M, Aghajanshakeri, S H, Javaherypour, S, Shafiee, R, Emrani Bidi, R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 5500
container_issue 6
container_start_page 5493
container_title Tumor biology
container_volume 35
creator Javanbakht, J
Pedram, B
Taheriyan, M R
Khadivar, F
Hosseini, S H
Abdi, F S
Hosseini, E
Moloudizargari, M
Aghajanshakeri, S H
Javaherypour, S
Shafiee, R
Emrani Bidi, R
description In this study, 12 dogs affected by canine transmissible venereal tumor (CTVT) and testicular seminoma tumor were studied retrospectively. The cytological sample was smeared onto a glass slide and either air-dried for May-Grünwald-stain, and masses were surgically removed. The tumors were grossly examined, and sections of 4-μm thick were obtained from each sample and stained with H&E. For chemotherapy, vincristine sulfate was administered weekly as an infusion over 3 min via the cephalic vein at a dose of 0.025 mg/kg after diluting with physiological saline to a total amount of 10 ml. If no remission was observed after 8 weeks, chemotherapy was continued with weekly doxorubicin infusion at a dose of 1 mg/kg. All the tumor samples were divided into four cytohistopathologic groups, namely: multilobular (six cases), papillary (two cases), pedunculated (two cases), and tubular (two cases of seminoma). The most frequently represented tumor type was multilobular (6/10, 60 %) followed by pedunculated (2/10, 20 %), papillary (2/10, 20 %), and tubular (two cases of seminoma, 100 %). Cytological smears from eight tumors in regression after chemotherapy were poorly cellular, and many cells were fragmented. In two progressive tumors, there was an average of 1,406 ± 972 CTVT 200 cells/μl or 96.71 % of total cells counted. Thus, tumor cells represented 96.71 % of total cells within the biopsy specimens and the leukocytes 4.29 % (leukocyte, tumor cell ratio=0.062 ± 0.031). In eight regressive tumors, there was an average of 1,245 ± 1,032 CTVT 200 cells/μl or 97.31 % of total cells counted. Thus, tumor cells represented 97.31 % of total cells and leukocytes 2.69 % (leukocyte, tumor cell ratio=0.071 ± 0.174). Our data suggested that combination treatment with vincristine and doxorubicin in the future could be an excellent therapeutic alternative for the treatment of TVT for probably reducing the resistance to vincristine, and also, treatment success could easily be followed by the cytological changes.
doi_str_mv 10.1007/s13277-014-1723-5
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1535632491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3331476601</sourcerecordid><originalsourceid>FETCH-LOGICAL-p309t-fecd94a800b5fbf62d2c57ccef51abfe314466d5da93a79ab2720bd5e77a653a3</originalsourceid><addsrcrecordid>eNpdkclO5TAQRS3UiPkD2CBLvWET8Bi_9K71xCQhsYH1UyWuvAQldrCdRvkfPhQz9KJ7VVeqU7dKtwg55eyCM2YuI5fCmIJxVXAjZKF3yAFXWTC5Yj-yZpwVSqzkPjmM8Zkxrquq3CP7QmlttBIH5G0NrndIUwAXxz7Gvh6Q_kGHAWGgaR59oOAsjTj2zo_wiwJtluS7PiY_Qer84LfLJ9J0OPrUYYBpoTHNdqG-_bKItHc0t-g2-NfU0amDiJ9Ddg6929KA24B5u3cU2oThH7NjstvCEPHkux6Rp-urx_Vtcf9wc7f-fV9MklWpaLGxlYIVY7Vu67YUVjTaNA22mkPdouRKlaXVFioJpoJaGMFqq9EYKLUEeUTOv3yn4F9mjGmTE2lwGMChn-OGa6lLKVTFM_rzP_TZz8Hl6z4olb9heJWps29qrke0myn0I4Rl8zd_-Q5AR4y8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1534723719</pqid></control><display><type>article</type><title>Canine transmissible venereal tumor and seminoma: a cytohistopathology and chemotherapy study of tumors in the growth phase and during regression after chemotherapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Javanbakht, J ; Pedram, B ; Taheriyan, M R ; Khadivar, F ; Hosseini, S H ; Abdi, F S ; Hosseini, E ; Moloudizargari, M ; Aghajanshakeri, S H ; Javaherypour, S ; Shafiee, R ; Emrani Bidi, R</creator><creatorcontrib>Javanbakht, J ; Pedram, B ; Taheriyan, M R ; Khadivar, F ; Hosseini, S H ; Abdi, F S ; Hosseini, E ; Moloudizargari, M ; Aghajanshakeri, S H ; Javaherypour, S ; Shafiee, R ; Emrani Bidi, R</creatorcontrib><description>In this study, 12 dogs affected by canine transmissible venereal tumor (CTVT) and testicular seminoma tumor were studied retrospectively. The cytological sample was smeared onto a glass slide and either air-dried for May-Grünwald-stain, and masses were surgically removed. The tumors were grossly examined, and sections of 4-μm thick were obtained from each sample and stained with H&amp;E. For chemotherapy, vincristine sulfate was administered weekly as an infusion over 3 min via the cephalic vein at a dose of 0.025 mg/kg after diluting with physiological saline to a total amount of 10 ml. If no remission was observed after 8 weeks, chemotherapy was continued with weekly doxorubicin infusion at a dose of 1 mg/kg. All the tumor samples were divided into four cytohistopathologic groups, namely: multilobular (six cases), papillary (two cases), pedunculated (two cases), and tubular (two cases of seminoma). The most frequently represented tumor type was multilobular (6/10, 60 %) followed by pedunculated (2/10, 20 %), papillary (2/10, 20 %), and tubular (two cases of seminoma, 100 %). Cytological smears from eight tumors in regression after chemotherapy were poorly cellular, and many cells were fragmented. In two progressive tumors, there was an average of 1,406 ± 972 CTVT 200 cells/μl or 96.71 % of total cells counted. Thus, tumor cells represented 96.71 % of total cells within the biopsy specimens and the leukocytes 4.29 % (leukocyte, tumor cell ratio=0.062 ± 0.031). In eight regressive tumors, there was an average of 1,245 ± 1,032 CTVT 200 cells/μl or 97.31 % of total cells counted. Thus, tumor cells represented 97.31 % of total cells and leukocytes 2.69 % (leukocyte, tumor cell ratio=0.071 ± 0.174). Our data suggested that combination treatment with vincristine and doxorubicin in the future could be an excellent therapeutic alternative for the treatment of TVT for probably reducing the resistance to vincristine, and also, treatment success could easily be followed by the cytological changes.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-014-1723-5</identifier><identifier>PMID: 24557542</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cellular biology ; Chemotherapy ; Dog Diseases - drug therapy ; Dog Diseases - pathology ; Dogs ; Doxorubicin - administration &amp; dosage ; Female ; Male ; Pathology ; Retrospective Studies ; Seminoma - drug therapy ; Seminoma - pathology ; Seminoma - veterinary ; Testicular Neoplasms - drug therapy ; Testicular Neoplasms - pathology ; Testicular Neoplasms - veterinary ; Tumors ; Venereal Tumors, Veterinary - drug therapy ; Venereal Tumors, Veterinary - pathology ; Vincristine - administration &amp; dosage</subject><ispartof>Tumor biology, 2014-06, Vol.35 (6), p.5493-5500</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24557542$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Javanbakht, J</creatorcontrib><creatorcontrib>Pedram, B</creatorcontrib><creatorcontrib>Taheriyan, M R</creatorcontrib><creatorcontrib>Khadivar, F</creatorcontrib><creatorcontrib>Hosseini, S H</creatorcontrib><creatorcontrib>Abdi, F S</creatorcontrib><creatorcontrib>Hosseini, E</creatorcontrib><creatorcontrib>Moloudizargari, M</creatorcontrib><creatorcontrib>Aghajanshakeri, S H</creatorcontrib><creatorcontrib>Javaherypour, S</creatorcontrib><creatorcontrib>Shafiee, R</creatorcontrib><creatorcontrib>Emrani Bidi, R</creatorcontrib><title>Canine transmissible venereal tumor and seminoma: a cytohistopathology and chemotherapy study of tumors in the growth phase and during regression after chemotherapy</title><title>Tumor biology</title><addtitle>Tumour Biol</addtitle><description>In this study, 12 dogs affected by canine transmissible venereal tumor (CTVT) and testicular seminoma tumor were studied retrospectively. The cytological sample was smeared onto a glass slide and either air-dried for May-Grünwald-stain, and masses were surgically removed. The tumors were grossly examined, and sections of 4-μm thick were obtained from each sample and stained with H&amp;E. For chemotherapy, vincristine sulfate was administered weekly as an infusion over 3 min via the cephalic vein at a dose of 0.025 mg/kg after diluting with physiological saline to a total amount of 10 ml. If no remission was observed after 8 weeks, chemotherapy was continued with weekly doxorubicin infusion at a dose of 1 mg/kg. All the tumor samples were divided into four cytohistopathologic groups, namely: multilobular (six cases), papillary (two cases), pedunculated (two cases), and tubular (two cases of seminoma). The most frequently represented tumor type was multilobular (6/10, 60 %) followed by pedunculated (2/10, 20 %), papillary (2/10, 20 %), and tubular (two cases of seminoma, 100 %). Cytological smears from eight tumors in regression after chemotherapy were poorly cellular, and many cells were fragmented. In two progressive tumors, there was an average of 1,406 ± 972 CTVT 200 cells/μl or 96.71 % of total cells counted. Thus, tumor cells represented 96.71 % of total cells within the biopsy specimens and the leukocytes 4.29 % (leukocyte, tumor cell ratio=0.062 ± 0.031). In eight regressive tumors, there was an average of 1,245 ± 1,032 CTVT 200 cells/μl or 97.31 % of total cells counted. Thus, tumor cells represented 97.31 % of total cells and leukocytes 2.69 % (leukocyte, tumor cell ratio=0.071 ± 0.174). Our data suggested that combination treatment with vincristine and doxorubicin in the future could be an excellent therapeutic alternative for the treatment of TVT for probably reducing the resistance to vincristine, and also, treatment success could easily be followed by the cytological changes.</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cellular biology</subject><subject>Chemotherapy</subject><subject>Dog Diseases - drug therapy</subject><subject>Dog Diseases - pathology</subject><subject>Dogs</subject><subject>Doxorubicin - administration &amp; dosage</subject><subject>Female</subject><subject>Male</subject><subject>Pathology</subject><subject>Retrospective Studies</subject><subject>Seminoma - drug therapy</subject><subject>Seminoma - pathology</subject><subject>Seminoma - veterinary</subject><subject>Testicular Neoplasms - drug therapy</subject><subject>Testicular Neoplasms - pathology</subject><subject>Testicular Neoplasms - veterinary</subject><subject>Tumors</subject><subject>Venereal Tumors, Veterinary - drug therapy</subject><subject>Venereal Tumors, Veterinary - pathology</subject><subject>Vincristine - administration &amp; dosage</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkclO5TAQRS3UiPkD2CBLvWET8Bi_9K71xCQhsYH1UyWuvAQldrCdRvkfPhQz9KJ7VVeqU7dKtwg55eyCM2YuI5fCmIJxVXAjZKF3yAFXWTC5Yj-yZpwVSqzkPjmM8Zkxrquq3CP7QmlttBIH5G0NrndIUwAXxz7Gvh6Q_kGHAWGgaR59oOAsjTj2zo_wiwJtluS7PiY_Qer84LfLJ9J0OPrUYYBpoTHNdqG-_bKItHc0t-g2-NfU0amDiJ9Ddg6929KA24B5u3cU2oThH7NjstvCEPHkux6Rp-urx_Vtcf9wc7f-fV9MklWpaLGxlYIVY7Vu67YUVjTaNA22mkPdouRKlaXVFioJpoJaGMFqq9EYKLUEeUTOv3yn4F9mjGmTE2lwGMChn-OGa6lLKVTFM_rzP_TZz8Hl6z4olb9heJWps29qrke0myn0I4Rl8zd_-Q5AR4y8</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Javanbakht, J</creator><creator>Pedram, B</creator><creator>Taheriyan, M R</creator><creator>Khadivar, F</creator><creator>Hosseini, S H</creator><creator>Abdi, F S</creator><creator>Hosseini, E</creator><creator>Moloudizargari, M</creator><creator>Aghajanshakeri, S H</creator><creator>Javaherypour, S</creator><creator>Shafiee, R</creator><creator>Emrani Bidi, R</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140601</creationdate><title>Canine transmissible venereal tumor and seminoma: a cytohistopathology and chemotherapy study of tumors in the growth phase and during regression after chemotherapy</title><author>Javanbakht, J ; Pedram, B ; Taheriyan, M R ; Khadivar, F ; Hosseini, S H ; Abdi, F S ; Hosseini, E ; Moloudizargari, M ; Aghajanshakeri, S H ; Javaherypour, S ; Shafiee, R ; Emrani Bidi, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p309t-fecd94a800b5fbf62d2c57ccef51abfe314466d5da93a79ab2720bd5e77a653a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cellular biology</topic><topic>Chemotherapy</topic><topic>Dog Diseases - drug therapy</topic><topic>Dog Diseases - pathology</topic><topic>Dogs</topic><topic>Doxorubicin - administration &amp; dosage</topic><topic>Female</topic><topic>Male</topic><topic>Pathology</topic><topic>Retrospective Studies</topic><topic>Seminoma - drug therapy</topic><topic>Seminoma - pathology</topic><topic>Seminoma - veterinary</topic><topic>Testicular Neoplasms - drug therapy</topic><topic>Testicular Neoplasms - pathology</topic><topic>Testicular Neoplasms - veterinary</topic><topic>Tumors</topic><topic>Venereal Tumors, Veterinary - drug therapy</topic><topic>Venereal Tumors, Veterinary - pathology</topic><topic>Vincristine - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Javanbakht, J</creatorcontrib><creatorcontrib>Pedram, B</creatorcontrib><creatorcontrib>Taheriyan, M R</creatorcontrib><creatorcontrib>Khadivar, F</creatorcontrib><creatorcontrib>Hosseini, S H</creatorcontrib><creatorcontrib>Abdi, F S</creatorcontrib><creatorcontrib>Hosseini, E</creatorcontrib><creatorcontrib>Moloudizargari, M</creatorcontrib><creatorcontrib>Aghajanshakeri, S H</creatorcontrib><creatorcontrib>Javaherypour, S</creatorcontrib><creatorcontrib>Shafiee, R</creatorcontrib><creatorcontrib>Emrani Bidi, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Javanbakht, J</au><au>Pedram, B</au><au>Taheriyan, M R</au><au>Khadivar, F</au><au>Hosseini, S H</au><au>Abdi, F S</au><au>Hosseini, E</au><au>Moloudizargari, M</au><au>Aghajanshakeri, S H</au><au>Javaherypour, S</au><au>Shafiee, R</au><au>Emrani Bidi, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Canine transmissible venereal tumor and seminoma: a cytohistopathology and chemotherapy study of tumors in the growth phase and during regression after chemotherapy</atitle><jtitle>Tumor biology</jtitle><addtitle>Tumour Biol</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>35</volume><issue>6</issue><spage>5493</spage><epage>5500</epage><pages>5493-5500</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>In this study, 12 dogs affected by canine transmissible venereal tumor (CTVT) and testicular seminoma tumor were studied retrospectively. The cytological sample was smeared onto a glass slide and either air-dried for May-Grünwald-stain, and masses were surgically removed. The tumors were grossly examined, and sections of 4-μm thick were obtained from each sample and stained with H&amp;E. For chemotherapy, vincristine sulfate was administered weekly as an infusion over 3 min via the cephalic vein at a dose of 0.025 mg/kg after diluting with physiological saline to a total amount of 10 ml. If no remission was observed after 8 weeks, chemotherapy was continued with weekly doxorubicin infusion at a dose of 1 mg/kg. All the tumor samples were divided into four cytohistopathologic groups, namely: multilobular (six cases), papillary (two cases), pedunculated (two cases), and tubular (two cases of seminoma). The most frequently represented tumor type was multilobular (6/10, 60 %) followed by pedunculated (2/10, 20 %), papillary (2/10, 20 %), and tubular (two cases of seminoma, 100 %). Cytological smears from eight tumors in regression after chemotherapy were poorly cellular, and many cells were fragmented. In two progressive tumors, there was an average of 1,406 ± 972 CTVT 200 cells/μl or 96.71 % of total cells counted. Thus, tumor cells represented 96.71 % of total cells within the biopsy specimens and the leukocytes 4.29 % (leukocyte, tumor cell ratio=0.062 ± 0.031). In eight regressive tumors, there was an average of 1,245 ± 1,032 CTVT 200 cells/μl or 97.31 % of total cells counted. Thus, tumor cells represented 97.31 % of total cells and leukocytes 2.69 % (leukocyte, tumor cell ratio=0.071 ± 0.174). Our data suggested that combination treatment with vincristine and doxorubicin in the future could be an excellent therapeutic alternative for the treatment of TVT for probably reducing the resistance to vincristine, and also, treatment success could easily be followed by the cytological changes.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>24557542</pmid><doi>10.1007/s13277-014-1723-5</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1010-4283
ispartof Tumor biology, 2014-06, Vol.35 (6), p.5493-5500
issn 1010-4283
1423-0380
language eng
recordid cdi_proquest_miscellaneous_1535632491
source MEDLINE; SpringerLink Journals
subjects Animals
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cellular biology
Chemotherapy
Dog Diseases - drug therapy
Dog Diseases - pathology
Dogs
Doxorubicin - administration & dosage
Female
Male
Pathology
Retrospective Studies
Seminoma - drug therapy
Seminoma - pathology
Seminoma - veterinary
Testicular Neoplasms - drug therapy
Testicular Neoplasms - pathology
Testicular Neoplasms - veterinary
Tumors
Venereal Tumors, Veterinary - drug therapy
Venereal Tumors, Veterinary - pathology
Vincristine - administration & dosage
title Canine transmissible venereal tumor and seminoma: a cytohistopathology and chemotherapy study of tumors in the growth phase and during regression after chemotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T10%3A54%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Canine%20transmissible%20venereal%20tumor%20and%20seminoma:%20a%20cytohistopathology%20and%20chemotherapy%20study%20of%20tumors%20in%20the%20growth%20phase%20and%20during%20regression%20after%20chemotherapy&rft.jtitle=Tumor%20biology&rft.au=Javanbakht,%20J&rft.date=2014-06-01&rft.volume=35&rft.issue=6&rft.spage=5493&rft.epage=5500&rft.pages=5493-5500&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-014-1723-5&rft_dat=%3Cproquest_pubme%3E3331476601%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1534723719&rft_id=info:pmid/24557542&rfr_iscdi=true